ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 広島大学の刊行物
  2. Hiroshima Journal of Medical Sciences
  3. 38巻4号

DNA Topoisomerase : the Mechanism of Resistance to DNA Topoisomerase II Inhibitor VP-16

https://hiroshima.repo.nii.ac.jp/records/2013243
https://hiroshima.repo.nii.ac.jp/records/2013243
09f13981-a1c2-45de-9394-393ee6352bf1
名前 / ファイル ライセンス アクション
HiroshimaJMedSci_38_197.pdf HiroshimaJMedSci_38_197.pdf (640.4 KB)
Item type デフォルトアイテムタイプ_(フル)(1)
公開日 2023-03-18
タイトル
タイトル DNA Topoisomerase : the Mechanism of Resistance to DNA Topoisomerase II Inhibitor VP-16
言語 en
作成者 Hong, Jae Hoon

× Hong, Jae Hoon

en Hong, Jae Hoon

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
主題
主題Scheme Other
主題 DNA topoisomernse II
主題
主題Scheme Other
主題 VP-16
主題
主題Scheme Other
主題 Drug resistance
主題
主題Scheme NDC
主題 490
内容記述
内容記述 K6-1 and 50B-3 cell lines, resistant to VP-16, a DNA topoisomerase II inhibitor, were established from two different types of cells respectively: human T-cell derived acute lymphoblastic leukemia cell line RPMI8402 and mouse mammary tumor cell line FM3A. IC50 values of K6-1 and 50B-3 cells to VP-I6, evaluated by the colony forming ability on methyl cellulose medium, were 11- and 84-fold higher than their sensitive parental cell lines, respectively. Membrane permeability of the drug was not responsible for the resistance in K6-l and 50B-3 cells. Quantitative analysis of drug-induced DNA cleavage (so called cleavable complex formation) was performed using 32P end-labeled pBR322 restriction fragments. The formation of the topoisomerase II-DNA cleavable complex stimulated by VP-16 in 50B-3 cells was approximately 1/5 compared with that of FM3A wild-type cells. Dot blot analysis of RNA extracted from these cell lines showed that the levels of mRNA for DNA topoisomerase II in 50B-3 cells were markedly decreased and that catalytic activity was reduced to 1/2-113 compared with that of parent cells. There was a slight reduction of DNA topoisomerase II mRNA in K6-1 cells. However, DNA topoisomerase II activities were similar in wild-type and K6-1 cells. In addition, 50B-3 cells showed cross resistance to VM-26, m-AMSA and adriamycin, whereas K6-1 cells exhibited increased resistance only to VM-26. These resistant cell lines did not show collateral sensitivity to CPT-11, a DNA topoisomerase I inhibitor. Southern blot analysis of genomic DNA did not show any change in the restriction pattern of the DNA topoisomerase II gene between the parental and their resistant lines. These findings suggest that the reduced levels in DNA topoisomerase II contribute to the drug resistance of 50B-3 cells.
言語 en
内容記述
内容記述タイプ Other
内容記述 Earlier versions of this work were presented at the 47th Annual Meeting of the Japanese Cancer Association (1988, Tokyo) and at the 51th Annual Meeting of the Japanese Hematological Society (1989, Gunma).
出版者
出版者 Hiroshima University Medical Press
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
関連情報
識別子タイプ PMID
関連識別子 2561562
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 0018-2052
収録物識別子
収録物識別子タイプ NCID
収録物識別子 AA00664312
開始ページ
開始ページ 197
書誌情報 Hiroshima Journal of Medical Sciences
Hiroshima Journal of Medical Sciences

巻 38, 号 4, p. 197-207, 発行日 1989-12
旧ID 38131
戻る
0
views
See details
Views

Versions

Ver.1 2025-02-23 06:27:38.634277
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3